Research on biomarker-driven therapy and immune check-point blockade in non-small cell
lung cancer (NSCLC) is rapidly evolving. The width and depth of clinical trials have also …

Over the past decade, targeted therapy for oncogene-driven NSCLC and immune
checkpoint inhibitors for non-oncogene-driven NSCLC, respectively, have greatly improved …

The clinical outcome of resectable non–small‐cell lung cancer (NSCLC) patients receiving
neoadjuvant chemoimmunotherapy is good but varies greatly. In addition, the pathological …

The genomic instability (GI)/homologous recombination deficiency (HRD) score, calculated
as the sum of the events of loss of heterozygosity (LOH), large-scale state transition (LST) …

The use of immune checkpoint inhibitors (ICIs) has become mainstream in the treatment of
non-small cell lung cancer (NSCLC). The idea of harnessing the immune system to fight …

Pancreatic ductal adenocarcinoma (PDA) is highly aggressive and has few treatment
options. To personalize therapy, it is critical to delineate molecular subtypes and understand …

Skin cancers, including basal cell carcinoma (BCC), cutaneous squamous cell carcinoma
(SCC), and melanoma, are the most common malignancies in the United States. Loss of …

Abstract The ferredoxin 1 (FDX1) gene had been recently reported as a critical mediator of
cuproptosis, and without doubt, its roles in KIRC would be of importance. Hence, this paper …

Studying the molecular mechanisms and regulatory functions of genes is crucial for
exploring new approaches and tactics in cancer therapy. Studies have shown that the …

Immune checkpoint inhibitors (ICIs) are highly concerned in the treatment of non-small cell
lung cancer (NSCLC), represented by inhibitors of programmed death protein 1 (PD-1) and …